ViiV Healthcare’s two-drug HIV regimen of Tivicay and Epivir has hit targets in late-stage trials, showing non-inferiority to a three-drug regimen and thus the potential to offer patients an alternative treatment strategy.
Read More
ViiV Healthcare, an HIV specialist firm majority owned by GlaxoSmithKline, has announced the launch of a late-stage study investigating the effectiveness of a two-drug regimen programme in patients with HIV.
Read More
ViiV Healthcare has kicked off a Phase III programme that it hopes will lead to regulatory filings for a two-drug regimen of Tivicay and Epivir as a treatment for HIV in adults who have not received prior antiretroviral therapy.
Read More
